BMS-599626 in Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

May 31, 2006

Conditions
CancerMetastases
Interventions
DRUG

panHer

Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.

Trial Locations (3)

Unknown

Local Institution, Scottsdale

Local Institution, Tucson

Local Institution, Los Angeles

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY